Denali Therapeutics

$62.23
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.12 (-0.19%) Today

$0.00 (0.00%) As of 9:04 PM UTC after-hours

Why Robinhood?

You can buy or sell DNLI and other stocks, options, and ETFs commission-free!

About DNLI

Denali Therapeutics Inc. Common Stock, also called Denali Therapeutics, is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA. The listed name for DNLI is Denali Therapeutics Inc. Common Stock.

CEO

Ryan J. Watts

Employees

261

Headquarters

San Francisco, California

Founded

2013

Market Cap

7.46B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

1.11M

High Today

$64.17

Low Today

$61.39

Open Price

$63.75

Volume

401.51K

52 Week High

$72.00

52 Week Low

$12.39

Collections

Analyst Ratings

73%

of 11 ratings

Buy

73%

Hold

27%

Sell

DNLI Earnings

-$0.61

-$0.41

-$0.20

$0.00

Q1 FY19

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Feb 25, After Hours